BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. announced today that Health Net, Inc. (NYSE: HNT) is the latest insurer to announce a positive coverage decision for the VeriStrat® test. Health Net published its coverage policy for the VeriStrat proteomic serum test on June 15th, stating the test is medically necessary for patients with, “…advanced NSCLC and wild-type (i.e., no mutation detected) EGFR or with unknown EGFR status.” Health Net’s coverage position on VeriStrat is included in its Na